ドラビリンの迅速開始における有効性と安全性 (RapiDO)
未治療HIV-1陽性患者におけるドラビリンの高活性抗レトロウイルス療法(HAART)迅速開始時の有効性と安全性
Protocol title: "Efficacy and safety of doravirine in the rapid initiation of highly active antiretroviral therapy (HAART) in HIV-1positive patients without prior treatment."
調査の概要
詳細な説明
Protocol number: FH-96
Primary objective: To evaluate the antiviral activity of DOR/3TC/TDF at week 48 in HIV.
Secondary objectives:
1. To evaluate the antiviral activity of DOR/3TC/TDF at < 200 coIPes/mL at week 48, using the intention-to-treat analysis (FDA snapshot analysis) for the exposed population (ITT-E). 2. To evaluate the antiviral activity of DOR/3TC/TDF at week 48 using an observed analysis (only including patients with available virological data).
3. To evaluate the antiviral activity of DOR/3TC/TDF in the subgroup of participants with baseline ITINN mutations that do not confer resistance to doravirine, (according to the list of mutations defined in the exclusion criteria) by calculating the proportion of patients with viral load <200 coIPes/mL and <50 coIPes/mL at week 48.
4. To evaluate the antiviral activity of DOR/3TC/TDF at <200 coIPes/mL and <50 coIPes/mL at week 24.
5. To evaluate the safety and tolerability of DOR/3TC/TDF. 6. To evaluate the antiviral activity of DOR/3TC/TDF at week 48 in patients with a baseline viral load >100,000 coIPes/mL.
7. Immune response: to evaluate immune recovery (CD4, CD8 and CD4/CD8 T-cell counts at weeks 24 and 48.
8. To evaluate the development of HIV-1 resistance in patients experiencing virological failure while undergoing treatment with DOR/3TC/TDF.
9. To assess changes in weight, BMI, and liIPd profile (total cholesterol, HDL, LDL and triglycerides) at weeks 24 and 48.
Study population: Subjects will be HIV-1 infection patient without ARV experience (naïve) within 30 days of diagnosis, willing to start ARV therapy in a rapid initiation setting, with ≥ 18 years of age, and who meet all inclusion criteria and do not meet any of the exclusion criteria.
Study design: Phase IV, multicenter, non-randomized, single-arm, open-label study describing the antiviral efficacy, safety, and tolerability of DOR/3TC/TDF therapy as rapid initiation therapy in subjects with HIV-1 infection who have not received prior treatment.
Regimens: Doravirine 100 mg; Lamivudine 300 mg; Tenofovir disoproxil 245 mg. Thirteen bottles. (Trade name: DELSTRIGO - MSD). Duration: 48 weeks.
Sample size: 100 subjects
研究の種類
入学 (推定)
段階
- フェーズ 4
連絡先と場所
研究連絡先
- 名前:María I Figueroa, MD
- 電話番号:2007 1121209999
- メール:maria.figueroa@huesped.org.ar
研究連絡先のバックアップ
- 名前:Pedro E Cahn, MD
- 電話番号:2007 1121209999
- メール:pedro.cahn@huesped.org.ar
研究場所
-
-
-
Buenos Aires、アルゼンチン、C1202ABB
- 募集
- Fundacion Huesped
-
コンタクト:
- Pedro E Cahn, MD; PhD
- 電話番号:21 (5411) 4981-7777
- メール:pcahn@huesped.org.ar
-
主任研究者:
- Pedro E Cahn, MD; PhD
-
-
Buenos Aires
-
Ciudad Autonoma de Buenos Aire、Buenos Aires、アルゼンチン、C1405CKC
- 募集
- Fundacion IDEAA -Infectologia de atencion ambulatoria
-
コンタクト:
- Ezequiel Cordova, MD
- 電話番号:011 49017133
- メール:dr_ecordova@hotmail.com
-
コンタクト:
- Norma Porteiro, MD
- 電話番号:011 49017133
- メール:normaporteiro@yahoo.com.ar
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
-
Subject has to voluntarily signed and dated an informed consent form, approved by an institutional ethics committee.
-
≥18 years of age.
-
Not previously exposed to ARV (naïve). Subject may have received oral PrEP and PEP within the last 6 months and injectable PrEP and PEP within the last year.
-
Have a received an HIV diagnosis within 30 days prior to selection. Defined as: Having confirmed HIV-1 infection. HIV-1 positive result is considered if the HIV1 RNA in plasma is ≥ 1000 copies/mL or two HIV antibody tests (using two different tests) are positive.
NOTE: Participants may be included without knowing their baseline viral load. If baseline viral load results are less than 1000 copies/mL, the volunteer's participation will be suspended and they will be considered to have failed the screening test. A viral load brought by the subject may be considered if it was performed within the last 30 days prior to the SCR visit.
-
CD4+ T-cell count: No limit.
-
Subjects able to meet the protocol requirements.
Exclusion Criteria:
-
History of hypersensitivity to doravirine, tenofovir, or lamivudine.
-
Severe hepatic impairment (Child-Pugh C).
-
Active HCV infection requiring specific treatment during study participation at the time of eligibility assessment. If HCV is diagnosed during the study and the participant requires treatment, the decision on whether to continue in the study will be at the investigator's discretion.
-
A woman may be eligible to enter and participate in the study if she is not pregnant (confirmed by a negative urine pregnancy test at the time of screening/baseline). If the baseline visit is scheduled on a different day than the SCR, the urine pregnancy test will be repeated) or breastfeeding and if at least one of the following conditions applies:
- Women without reproductive capacity, defined as premenopausal women with tubal ligation or hysterectomy, or documented bilateral oophorectomy; or as postmenopausal women with 12 months of spontaneous amenorrhea, and women ≥ 45 years of age without hormone replacement therapy.
- Women with reproductive capacity who agree to adopt one of the contraceptive options in Appendix 2 for at least 30 days after the last dose of study medication and/or completion of the follow-up visit.
The chosen contraceptive method must be used consistently, according to the approved product label. All study participants must be advised on safer sex practices, including the use of effective barrier methods, and the choice of effective contraceptive method must be documented in the eCRF (Electronic Case Report Form).
-
The subject's general health status, in the investigator's oIPnion, interferes with the requirements of the study.
-
Has a diagnosis of an active opportunistic infection defining AIDS or a malignant neoplasm within 30 days prior to evaluation (except Kaposi's sarcoma with fewer than 10 skin lesions).
-
Is participating or has participated in a clinical study in the last 6 months.
-
Creatinine clearance (CrCl) ≤50 mL/min according to the Cockcroft-Gault equation.
-
Any verified Grade 4 abnormality (except liIPds: HDL, LDL, total cholesterol, triglycerides).
-
History or presence of allergy to study drugs or their components, or to drugs in their class.
-
Subjects taking any medication during the study, including over-the-counter medications and herbal preparations, without the approval of the study physician.
-
Mutations resistant to doravirine, 3TC, or TDF, according to the list described below:
DOR mutations (INNTI):
Doravirine (INNTI) Primary: the presence of one or more ART-resistant mutations will be grounds for exclusion.
Mutations: V106A/M, F227C/V, L234I, Y188L, Y318F, M230I/L. Secondary: the presence of one or more RAMs will be grounds for exclusion. Mutations: A98G, V108I, G190E, H221Y, P225H, F227L, P236L. Others: the presence of five or more RAMs will be grounds for exclusion. Mutations: V90I, L100I, K101E/H/P, K103N/R/S, V106I, I135T, Y181C/I/V, E138A/G/K/Q/R, V170F/T, G190A/Q/S, Y188C/H, F227I, V245E, K311R.
NRTI (TDF) Relevant mutations: Presence of one or more RAM Mutations: K65R, insertion 69, K70R/E, Q151M,
NRTI (3TC) Relevant mutation Presence of IM184V
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Doravirine /Lamivudine/ Tenofovir Disoproxil
Doravirine 100 mg/Lamivudine 300 mg/Tenofovir disoproxilo245 mg |
Pharmaceutical form: Oral tablets Unit dose concentration/dose level(s): 100/300/245 mg Administration instructions: Take one tablet once a day
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Evaluate the antiviral activity of DOR/3TC/TDF at week 48 in HIV patients without prior antiretroviral treatment, in a rapid initiation setting.
時間枠:48 Weeks
|
Proportion of patients with a viral load < 50 copies/mL at week 48, as determined by an intention-to-treat analysis (FDA snapshot analysis) of the exposed population (ITT-E) |
48 Weeks
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Evaluate the antiviral activity of DOR/3TC/TDF at < 200 copies/mL at week 48, using the intention-to-treat analysis (FDA snapshot analysis) for the exposed population (ITT-E).
時間枠:48 Weeks
|
Proportion of patients with a viral load < 200 copies/mL at week 48, using intention-to-treat analysis (FDA snapshot analysis) for the exposed population (ITT-E). |
48 Weeks
|
|
Evaluate the antiviral activity of DOR/3TC/TDF at week 48 using an observed analysis (only including patients with available virological data).
時間枠:48 Weeks
|
Proportion of patients who achieved HIV-1 RNA levels <50 copies/mL at week 48, in those with available data (observed analysis) |
48 Weeks
|
|
Evaluate the antiviral activity of DOR/3TC/TDF in the subgroup of participants with baseline ITINN mutations that do not confer resistance to doravirine, by calculating the proportion of patients with viral load <200 c/mL and <50 c/mL at week 48.
時間枠:48 Weeks
|
Proportion of patients with viral load < 200 copies/mL and viral load < 50 copies/mL at week 48 in the subgroup of participants with baseline ITINN mutations that do not confer resistance to doravirine, according to the list of mutations defined in the exclusion criteria. |
48 Weeks
|
|
Evaluate the antiviral activity of DOR/3TC/TDF at <200 copies/mL and <50 copies/mL at week 24.
時間枠:24 Weeks
|
Proportion of patients with viral load < 200 copies/mL and viral load < 50 copies/mL at week 24, using intention-to-treat analysis (FDA snapshot analysis) for the exposed population (ITT-E). |
24 Weeks
|
|
Evaluate the safety and tolerability of DOR/3TC/TDF.
時間枠:52 Weeks
|
Frequency, type, severity, and seriousness of adverse events and laboratory abnormalities, and proportion of patients who discontinued treatment with DOR/3TC/TDF due to adverse events or death |
52 Weeks
|
|
Evaluate the antiviral activity of DOR/3TC/TDF at week 48 in patients with a baseline viral load >100,000 copies/mL.
時間枠:48 Weeks
|
Proportion of patients with a baseline HIV-1 RNA level >100,000 c/mL who achieve virological suppression below 50 copies/mL at week 48 (ITT-E analysis). |
48 Weeks
|
|
Immune response: evaluate immune recovery (CD4, CD8 and CD4/CD8 T-cell counts at weeks 24 and 48.
時間枠:24 and 48 Weeks
|
Changes in CD4 T-cell count, CD8 T-cell count, and CD4/CD8 ratio between baseline and weeks 24 and 48. |
24 and 48 Weeks
|
|
Evaluate the development of HIV-1 resistance in patients experiencing virological failure while undergoing treatment with DOR/3TC/TDF
時間枠:48 Weeks
|
Number and type of resistance mutations in cases of virological failure. |
48 Weeks
|
|
Assess changes in weight and BMI, at weeks 24 and 48.
時間枠:24 and 48 Weeks
|
Changes in weight and BMI between baseline and weeks 24 and 48. Weight and height will be combined to calculate BMI in kg/m^2. Weight will be measured at all visits and height only at the baseline visit. |
24 and 48 Weeks
|
|
Assess changes in lipid profile (total cholesterol, HDL, LDL and triglycerides) at weeks 24 and 48.
時間枠:24 and 48 Weeks
|
Changes in lipid profile (total cholesterol, HDL, LDL and triglycerides) between baseline and weeks 24 and 48. |
24 and 48 Weeks
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
追加の関連 MeSH 用語
その他の研究ID番号
- FH-96
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
It will be shared upon request, 6 months after last patient´s last visit. URL not yet available.
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。